Skip to content

    Astrazeneca Phar

    ASTRAZENGood
    Healthcare·14 Aug 2023
    Management Summary

    AstraZeneca India delivered a robust performance in FY23, characterized by significant double-digit growth in revenue and profitability. The company is successfully transitioning into a specialist organization, led by its dominant Oncology portfolio and expansion into Rare Diseases. While facing generic competition in some segments, management is leveraging a science-led innovation strategy and a dense pipeline of 15+ upcoming launches to drive long-term value.

    Highlights

    7

    • Product sales reached ₹947 crores (Rs. 9,470 million), representing a 24% YoY growth.

    • Total comprehensive income grew by 62% YoY to ₹96.7 crores (Rs. 967 million).

    • Oncology segment remains the largest contributor, with sales growing 43% YoY, outperforming the market growth of 25%.

    • Tagrisso emerged as the single largest product, contributing 23.3% of total sales with revenue of ₹219.1 crores.

    • The company maintained a zero-debt status with a book value per share of ₹235.50.

    • Management announced a dividend of ₹16 per share for the financial year 2022-23.

    • Launched Rare Disease therapy area with 'Koselugo' and plans to introduce 15+ new assets/indications over the next 3-4 years.

    What Changed1

    vs Q1 FY25

    Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Product Sales₹947 Cr+24%YoY
    2. 02Total Comprehensive Income₹96.7 Cr+62%YoY
    3. 03Profit Before Tax₹134 Cr
    4. 04Earnings Per Share₹39.7
    5. 05Employee Cost to Sales27.5%-9%YoY

    Segment breakdown

    Oncology
    43% Revenue Growth56% Sales Contribution
    CVRM (Cardiovascular, Renal and Metabolism)
    18% Revenue Growth
    Respiratory
    52% Revenue Growth
    List

    Guidance & targets

    3
    CategoryTargetPriority
    Volume
    New Asset/Indication Launches
    15+
    		High
    Revenue
    Turnover Milestone
    ₹3,000 crores
    		Medium
    Other
    Carbon Zero Goal
    Zero Carbon
    		High

    Risks & concerns

    5
    RiskSeverity

    Import Dependence

    High foreign exchange outflow is tied to the import of innovative medicines from the global parent. — Management acknowledged

    medium

    Generic Proliferation

    Loss of exclusivity for Dapagliflozin (Forxiga) has led to generic competition, though management claims proactive pricing is mitigating impact. — Management acknowledged

    medium

    Regulatory Approval Timelines

    The launch of 15+ new assets is strictly subject to Indian regulatory approvals and global timelines. — Management acknowledged

    medium

    Credit Loss Provisions

    Cyclical provisions for expected credit losses, primarily related to long recovery periods from government institutions. — Analyst acknowledged

    low

    Areas of Evasion(1)

    • Specific timeline for the ₹3,000 crore revenue target was not provided.

    Q&A highlights

    3

    “This has increased because we are, a lot of our products are imported, we are import dependent company hence the with the increase in sales, the increase in import hence the increase in the outflow.”

    Explains the significant gap between FX earnings (₹61.2 cr) and spend (₹374.7 cr) as a function of the business model.

    asked by Sadananda Shastri

    2 min read5 chapters

    Detailed Narrative

    01

    Oncology Portfolio Drives Outperformance

    The Oncology segment remains the bedrock of AstraZeneca India's growth, contributing 56% of total sales. Key brands like Tagrisso (₹219.1 cr) and Lynparza (₹130 cr) saw growth of 29% and 55% respectively. Imfinzi showed exceptional traction with 185% growth, reaching ₹100.7 cr in sales. The company is now the third fastest-growing oncology player in India, significantly outstripping the broader market growth rate.

    02

    Strategic Pivot to Rare Diseases

    AstraZeneca officially entered the Rare Disease therapy area this year with the launch of Koselugo for NF1 treatment. This follows the global acquisition of Alexion. Management plans to establish a dedicated Rare Disease business unit and is actively looking to bring clinical trials for this segment to India. This move is aligned with the updated national policy for rare diseases and increasing government funding in the sector.

    03

    Robust Pipeline and Launch Trajectory

    The company has a dense regulatory submission timeline, with over 15 new assets and indications planned for launch in the next 3-4 years. Notable upcoming treatments include Enhertu for HER2-expressing tumors and Tezspire. Management emphasized that the next 2-3 years are critical as they accelerate regulatory approvals to bring these innovative molecules to the Indian market.

    04

    Operational Efficiency and Sustainability

    AstraZeneca is making significant strides in its 'Ambition Zero Carbon' initiative, currently utilizing 95-97% green energy at its facilities. The factory maintained zero Lost Time Injuries and achieved 100% stock availability. Digital acceleration is also a key theme, with the launch of AI-powered diagnostic tools like Lung Mitra 2.0 and partnerships with technology firms like Qure.ai to improve patient identification and screening.

    05

    Financial Resilience and Shareholder Returns

    Despite being an import-dependent company with high FX outflows, AstraZeneca remains a zero-debt entity with strong cash reserves. Total comprehensive income rose 62% to ₹96.7 cr, and PBT reached ₹134 cr. The board recommended a dividend of ₹16 per share, reflecting a stable payout despite the heavy reinvestment required for new product launches and Phase IV clinical trials.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.